Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to Neurology Today about the news that the 48-week randomized, placebo-controlled phase 3 PHOENIX trial on Relyvrio did not meet its primary and secondary endpoints. The clinical trial had enrolled 664 adults with amyotrophic lateral sclerosis, or ALS.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH